This two week course on Arterial Pollution covered the field of atherosclerosis as a disease entity, and includes its anatomical, physiopathological, epidemiologic, preventi ve and therapeutic aspects. With the cooperation of an outstanding group of inter national lecturers we have been able to present an overview of the disease and its accidents as it stands today. Such a scope differs greatly from the narrow workshops which only consider biochemical disorders, e.g., the lipoproteins or the risk factors. We believe it was timely to study the entire physiopa thological entity of arterial pollution and we included all aspects of the disease in one single sweep. We are grateful to the Nato Advanced Institute Programs for accepting this topic on the list of their sponsored initiatives and especially Mr. di Lullo for his personal care. Whether we succeeded was proved by the audience to the Nato Advanced Study Institute at Maratea in September 1981 and will become clearer through the audience these proceedings will gain in the medical community. H. Peeters, editor A. Gresham, R. Paoletti, co-editors v CONTENTS An Integrated View on Atherosclerosis . • . . . . . . . .. . 1 H. Peeters 1. NATURAL HISTORY 1.1. Atherosclerosis: Its Origin and Development in Man. . 7 G.A. Gresham 1.2. Functional Aspects of Atherogenesis. • . . . . . 23 . K.W. Walton 2. ANIMAL MODELS 2.1. Animal Models of Atherosclerosis. . • . . . . . . 55 .

Inhalt
An Integrated View on Atherosclerosis.- 1. Natural History.- 1.1. Atherosclerosis: Its Origin and Development in Man.- 1.2. Functional Aspects of Atherogenesis.- 2. Animal Models.- 2.1. Animal Models of Atherosclerosis.- 2.2. Atherosclerosis in Animals: Comparative Aspects.- 3. Physiopathology.- 3.1. The Arterial Wall.- 3.2. The Myocardium.- 3.3. The Lipoproteins.- 3.4. The Hemostatic Mechanism.- 4. Epidemiology and Risk.- 4.1. Epidemiology of Atherosclerotic Heart Diseases.- 4.2. Hyperlipidemia as a Risk Factor.- 4.3. Diabetes: Is It a Risk Factor for Atherosclerosis ?.- 5. Prevention and Regression.- 5.1. Atherosclerosis: Clinical Features, Prevention and Regression.- 5.2. Prevention of Coronary Heart Disease Part I. Primary Prevention of Coronary Heart Disease.- 5.3. Prevention of Coronary Heart Disease Part II. Secondary Prevention of Coronary Heart Disease.- 6. Therapeutic Measures.- 6.1. Therapeutic Control of Atherogenous Primary Hyperlipidemias.- 6.2. Radical Therapy of Hypercholesterolaemia and Atherosclerosis.- 6.3. Drug Control of Hypercholesteremia and Platelet Function.